TY - JOUR
T1 - Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research
T2 - an EORTC-NCI working group report.
AU - Sweep, Fred C.G.J.
AU - Fritsche, Herbert A.
AU - Gion, Massimo
AU - Klee, George G.
AU - Schmitt, Manfred
PY - 2003/12
Y1 - 2003/12
N2 - A major dilemma associated with immuno(metric) assays for biomarkers is that various kits employing antibodies with differing specificities and binding affinities may generate non-equivalent test results. Also, variation in sample processing and the use of different standards (reference material) may result in discordant test results. Therefore, assays and procedures should be standardized and the quality of biomarker assay results should be monitored by continuous between-laboratory proficiency testing of performance. External quality control requires an established network of expert laboratories in which the investigators interact freely and where technical issues are discussed. Although such networking is more often praised than practiced, we strongly endorse and advocate between-laboratory exchange of experience and information. The present study discusses analytical aspects of immuno(metric) biomarker assays and presents recommendations of the Receptor and Biomarker Group of the EORTC (European Organisation for Research and Treatment of Cancer) how such tests should be validated for first time and day to day use. Moreover, a model for an appropriate quality assurance program is presented.
AB - A major dilemma associated with immuno(metric) assays for biomarkers is that various kits employing antibodies with differing specificities and binding affinities may generate non-equivalent test results. Also, variation in sample processing and the use of different standards (reference material) may result in discordant test results. Therefore, assays and procedures should be standardized and the quality of biomarker assay results should be monitored by continuous between-laboratory proficiency testing of performance. External quality control requires an established network of expert laboratories in which the investigators interact freely and where technical issues are discussed. Although such networking is more often praised than practiced, we strongly endorse and advocate between-laboratory exchange of experience and information. The present study discusses analytical aspects of immuno(metric) biomarker assays and presents recommendations of the Receptor and Biomarker Group of the EORTC (European Organisation for Research and Treatment of Cancer) how such tests should be validated for first time and day to day use. Moreover, a model for an appropriate quality assurance program is presented.
UR - http://www.scopus.com/inward/record.url?scp=1642413093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1642413093&partnerID=8YFLogxK
U2 - 10.3892/ijo.23.6.1715
DO - 10.3892/ijo.23.6.1715
M3 - Article
C2 - 14612946
AN - SCOPUS:1642413093
VL - 23
SP - 1715
EP - 1726
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 6
ER -